



ASX/Media Announcement

Monash IVF Group Limited (ASX: MVF)

5 July 2017

The Directors of Monash IVF Group (“Monash” or “the company”) (ASX: MVF) wish to respond to the recent article published in the Australian Financial Review (AFR) dated 1 July 2017.

Monash is, and has always been committed to doing everything possible to assist every one of its patients to create a family. Monash doctors, nurses and laboratory staff work together to achieve this outcome.

Recent comments by an unnamed source in the AFR citing an “ongoing problem” between Monash and its doctors are speculative and inaccurate.

Nothing is more important and critical to the success of Monash than providing industry best IVF services and success rates. Monash has been providing the highest quality IVF services for more than 40 years. In this time, more than 35,000 babies have been born with our expert help.

Monash takes its continuous disclosure obligations seriously and is comfortable it has complied with its obligations in respect of the cessation of Dr Lynn Burmeister with Monash.

Doctor engagement model and Monash IVF Group:

Professor Luk Rombauts, Group Medical Director of Monash IVF Group notes;

“The Monash IVF Group medical engagement model with its fertility specialists has never been stronger. The doctor group are highly engaged and committed to the organisation.”

“Any talk of tension between Monash IVF Group and its doctors is wrong. Both the doctor group and Monash IVF Group management are focused on the same thing: doing all we can to support the success of our patients.”

“Recent initiatives including the establishment of the Group Medical Advisory Committee (GMAC) and the Group Medical Executive Committee (GMEC) ensure appropriate consultation and communication in relation to relevant commercial and operational matters with medical practitioners occurs across the Group.”

“Monash IVF remains a pre-eminent partner of choice for not only established fertility specialists but for the next generation of up and coming fertility specialists”.

On the impending departure of Dr Lynn Burmeister:

- Dr Burmeister negotiated through her lawyers all her contractual arrangements with Monash IVF which included restraints of trade. In 2013, Dr Burmeister further negotiated a new arrangement with Monash IVF through her lawyers which involved Monash IVF accepting a renegotiated restraint of trade put forward by Dr Burmeister and her lawyers.
- Dr Burmeister received shares and other considerations for these contractual arrangements. Monash IVF is seeking to do no more than hold Dr Burmeister to the contracts that she freely entered into and negotiated through her lawyers and which she accepted as recently as in 2013 as being reasonable.
- Dr Burmeister's success comes in no small way from the significant backing and investment Monash IVF Group has made in the development and support of her practice, and the leading edge clinical technology to which we have given her access including extended embryo culture development, snap-freezing of embryos and eggs, genetic embryo testing using next generation sequencing and sperm and egg donor options.
- Dr Burmeister has benefited from the support of nursing, laboratory and administrative staff and systems provided by Monash IVF Group to provide world class services to our patients.
- Dr Burmeister has worked with and used Monash IVF for in excess of 17 years. Her success would not have been achieved without the world class facilities made available by Monash IVF. It would not be possible for a single doctor to independently deliver an appropriate level of care to these patients.
- Consistent with the cooperative and collegiate culture and its integrated services delivery model, Dr Burmeister's fellow fertility specialists at Monash IVF have participated and provided services to these patients. An example of this is Dr Burmeister's colleagues perform the vast majority of the egg collections on her behalf. Dr Burmeister has benefitted from the advances of her Monash IVF colleagues. It is this broader support network of Monash IVF Group fertility specialists and scientific staff, and their time and dedication that has been a key driver of Dr Burmeister's success and patient workload.

...Ends...

Contact details

James Thiedeman
Chief Executive Officer
Monash IVF Group Limited
Tel: +61 (0) 3 9420 8235

Michael Knaap
Chief Financial Officer & Company Secretary
Monash IVF Group Limited
Tel: +61 (0) 3 9420 8235

About Monash IVF Group

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.